Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full com…
Kuros Biosciences AG
Kuros statement on media inquiry concerning former Board member
Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, has become aware of…
Kuros Biosciences announces changes in the Board of Directors
Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, announces that Alber…
Kuros Biosciences Reports First Half of 2025 Results
Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales…
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completio…
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in t…
Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual Gene…
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
Financial & Operational Highlights Direct MagnetOs™ sales increased by 79% to USD 28.4 million in Q1 2025 (Q1 2024: US…
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sa…
Kuros Biosciences Expands into Extremities Markets
Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration be…
